Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Financial News

Foghorn launches with $50M for chromatin remodeling platform

March 14, 2018 11:07 PM UTC

Flagship Pioneering's Flagship VentureLabs launched chromatin remodeling company Foghorn Therapeutics Inc. (Cambridge, Mass.) with a $50 million capital commitment. Foghorn's Gene Traffic Control platform identifies small molecules capable of regulating chromatin remodeling complexes, which determine whether particular genes are physically accessible for transcription and eventually expressed as protein.

Foghorn President and CEO Adrian Gottschalk told BioCentury that the initial focus will be on modulating undisclosed components of the SWI/SNF chromatin remodeling complex or its associated transcription factors. The complex is mutated in about 20% of cancers, Gottschalk said...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article